Skip to Content

The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.


This page contains information on GentaOtic for veterinary use.
The information provided typically includes the following:
  • GentaOtic Indications
  • Warnings and cautions for GentaOtic
  • Direction and dosage information for GentaOtic


This treatment applies to the following species:
Manufacturer: Butler Schein™ Animal Health


For the treatment of acute chronic otitis externa in dogs

Also for superficial infected lesions in dogs and cats

For use in Dogs and Cats only

GentaOtic Caution

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

ANADA #200-183, Approved by FDA.


GentaOtic Otic Solution is packaged in a convenient squeeze bottle for easy application. Each mL of GentaOtic Otic Solution contains gentamicin sulfate equivalent to 3 mg gentamicin base, betamethasone valerate equivalent to 1 mg betamethasone, 1.0 mg hydroxyethylcellulose, 2.5 mg glacial acetic acid, 200 mg purified water, 19% ethanol, 9.4 mg benzyl alcohol as preservative, 300 mg glycerin and propylene glycol q.s.

CHEMISTRY: Gentamicin is a bactericidal antibiotic of the aminoglycoside group derived from Micromonospora purpurea of the Actinomyces group. It is a powder, white to buff in color, basic in nature, readily soluble in water and highly stable in solution.

Betamethasone valerate is a synthetic corticosteroid derivative of prednisolone.

ACTION: GentaOtic Otic Solution combines the broad-spectrum activity of gentamicin sulfate with the anti-inflammatory and antipruritic activity of betamethasone valerate. In vitro antibacterial activity has shown that gentamicin is active against most gram-negative bacteria including Pseudomonas aeruginosa, indole-positive and negative Proteus sp., Escherichia coli, Klebsiella pneumoniae, Aerobacter aerogenes, and Neisseria. Gentamicin is also active against strains of gram-positive bacteria including Staphylococcus species and some Streptococcus species.

Betamethasone valerate has emerged from intensive research as the most promising of some 50 newly synthesized corticosteroids in the experimental model described by McKenzie et al. This human bioassay technique has been found reliable for evaluating the vasoconstrictor properties of new topical corticosteroids and is useful in predicting clinical efficacy.

Betamethasone valerate in human medicine had been shown to provide anti-inflammatory and antipruritic activity in the topical management of corticosteroid-responsive dermatoses. In the responsive cases, the local anti-inflammatory activity is sustained by the vasoconstrictor properties of the steroid.

TOXICITY STUDIES: Parenterally, no toxic effects were observed in rats given gentamicin sulfate 20 mg/kg/day for twenty-four days; in cats given 10 mg/kg/day for forty days. Gentamicin sulfate given to dogs at 6 mg/lb/day, 6 days weekly for three weeks, caused no detectable kidney damage. At higher doses, impairment of equilibrium and renal function were observed in these species.

Subacute otic toxicity in dogs showed gentamicin sulfate with betamethasone valerate solution to be well tolerated locally with no adverse systemic effects when administered at 5 drops twice a day for 21 consecutive days.

Gentamicin sulfate in a 21-day subacute dermal toxicity study in dogs was shown to be well tolerated when applied topically to abraded skin. There were no meaningful findings except a reduction in eosinophil count attributable to absorption of the corticosteroid component.

GentaOtic Indications

GentaOtic Otic Solution is indicated for the treatment of acute and chronic canine otitis externa and canine and feline superficial infected lesions caused by bacteria sensitive to gentamicin.

Dosage and Administration

Duration of treatment will depend upon the severity of the condition and the response obtained. The duration of treatment and/or frequency of the dosage may be reduced, but care should be taken not to discontinue therapy prematurely.

Otitis externa: The external ear and ear canal should be properly cleaned and dried before treatment. Remove foreign material, debris, crusted exudates, etc., with suitable non-irritating solutions. Excessive hair should be clipped from the treatment area of the external ear. Instill 3 to 8 drops of GentaOtic Otic Solution (approximately room temperature) into the ear canal twice daily for seven to fourteen days.

Superficial infected lesions: The lesion and adjacent area should be properly cleaned before treatment. Excessive hair should be removed. Apply a sufficient amount of GentaOtic Otic Solution to cover the treatment area twice daily for seven to fourteen days.


If hypersensitivity to any of the components occurs, treatment with this product should be discontinued and appropriate therapy instituted. Concomitant use of drugs known to induce ototoxicity should be avoided. This preparation should not be used in conditions where corticosteroids are contraindicated. Do not administer parenteral corticosteroids during treatment with GentaOtic Otic Solution.


The antibiotic sensitivity of the pathogenic organism should be determined prior to the use of this preparation. Use of topical antibiotics occasionally allows overgrowth of non-susceptible bacteria, fungi, or yeasts. In these cases, treatment should be instituted with other appropriate agents as indicated.

Adverse systemic reactions have been observed following the oral ingestion of some topical corticosteroid preparations. Patients should be closely observed for the usual signs of adrenocorticoid overdosage which includes sodium retention, potassium loss, fluid retention, weight gains, polydipsia and/or polyuria. Prolonged use or overdosage may produce adverse immunosuppressive effects.

Experimentally it has been demonstrated that corticosteroids, especially at high dosage levels, may result in delayed wound healing. An increase in the incidence of osteoporosis may be noted, mainly in the elderly, with prolonged use of these compounds. Their use in older dogs during the healing stages of bone fracture is not indicated for the reason listed above.

Use of corticosteroids depending on dose, duration, and specific steroid, may result in inhibition of endogenous steroid production following drug withdrawal. In patients presently receiving or recently withdrawn from systemic corticosteroid treatments, therapy with a rapidly acting corticosteroid should be considered in unusually stressful situations.

GentaOtic Caution

Before instilling any medication into the ear, examine the external ear canal thoroughly to be certain the tympanic membrane is not ruptured in order to avoid the possibility of transmitting infection to the middle ear as well as damaging the cochlea or vestibular apparatus from prolonged contact. If hearing or vestibular dysfunction in noted during the course of treatment, discontinue use of GentaOtic Otic Solution.


Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Additionally, corticosteroids may induce cleft palates in offspring when given to pregnant animals during the period of palate closure of the embryos. Other congenital anomalies including deformed forelegs, phocomelia, and anasarca have been reported in offspring of dogs which received corticosteroids during pregnancy. Avoid ingestion.

Side Effects

Side effects such as SAP and SGPT enzyme elevations, weight loss, anorexia, polydipsia, and polyuria have occurred following the use of parenteral or systemic synthetic corticosteroids in dogs. Vomiting and diarrhea (occasionally bloody) have been observed in dogs and cats.

Cushing's Syndrome in dogs has been reported in association with prolonged or repeated steroid therapy.


Store between 2°C and 25°C (36°F and 77°F).

How Supplied

GentaOtic Otic Solution, is available in squeeze bottles in the following sizes: 7.5 mL, 15 mL, 240 mL (8 fl oz)

NAC No.: 10822681

A Henry Schein Company

Telephone:   614-761-9095
Toll-Free:   1-888-691-2724 (My1-BSAH)
Every effort has been made to ensure the accuracy of the GentaOtic information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.

Copyright © 2018 North American Compendiums. Updated: 2018-04-26